Mycotoxins are low-molecular-weight secondary metabolites produced by fungi. Mycotoxins are considered a very important public health issue because of their adverse effects on animals and humans. Emerging mycotoxins are mycotoxins that are not routinely determined and are not legislatively regulated, including beauvericin and enniatins. Masked mycotoxins formed by conjugation with polar compounds, as a plant defense mechanism, are not analyzed by conventional methods and may be more toxic than the original mycotoxin.
The aim of the present study was to evaluate the in vitro efficacy of an anti-mycotoxins agent that contains selected binding material and natural extracts besides an exclusive combination of yeasts, against some emerging and masked mycotoxins.
MATERIALS AND METHODS
The innovative anti-mycotoxins agent tested in the present study is a promising strategy with high in vitro efficacy against emerging (beauvericin and enniantins) and masked (ZEN14-glucuronide) mycotoxins and low desorption under gastrointestinal conditions.